Ryan F Herde1, Kristine E Kokeny2, Chakravarthy B Reddy3, Wallace L Akerley4, Nan Hu5, Jonathan P Boltax3, Ying J Hitchcock2. 1. University of Utah School of Medicine. 2. Department of Radiation Oncology, Huntsman Cancer Hospital. 3. Department of Internal Medicine, Division of Pulmonary Medicine. 4. Department of Internal Medicine, Division of Oncology. 5. Department of Internal Medicine, Division of Epidemiology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Abstract
OBJECTIVES: Primary carcinoid tumors of the lung are rare tumors which comprise approximately 0.5% to 5% of all lung malignancies in adults and roughly 20% to 30% of all carcinoid tumors. The purpose of this retrospective, descriptive study was to describe the incidence, characteristics, and outcomes of patients treated for primary pulmonary carcinoid tumor at a single institution. MATERIALS AND METHODS: All patients with a diagnosis of primary pulmonary carcinoid tumor treated from 1989 to 2009 were reviewed. Data collected included demographics, pathology, tobacco use, clinical presentation, tumor location, tumor spread, treatment, and survival. RESULTS: There were 59 cases of pulmonary carcinoid tumors: 47 typical (80%) and 12 atypical (20%). All but 4 patients underwent surgery, including 54 (92%) lung-sparing resections and 1 pneumonectomy. Five of 55 patients received concurrent adjuvant chemoradiation therapy; 4 patients with atypical and 1 with typical histology. Three additional patients with atypical carcinoid were treated only with adjuvant radiotherapy, palliative radiotherapy, or palliative chemotherapy, respectively. The Kaplan-Meier 5- and 10-year overall survivals were both 80% within the entire population. In the 88% of patients who achieved complete remission, disease-free survival was 98%. A review of a large series from the literature is also presented. CONCLUSIONS: Surgical resection was primary and adequate therapy for most typical carcinoid tumors with high overall survival and disease-free survival. Adjuvant chemotherapy or radiotherapy might be considered for patients with atypical carcinoid tumors who present with adverse pathologic findings.
OBJECTIVES:Primary carcinoid tumors of the lung are rare tumors which comprise approximately 0.5% to 5% of all lung malignancies in adults and roughly 20% to 30% of all carcinoid tumors. The purpose of this retrospective, descriptive study was to describe the incidence, characteristics, and outcomes of patients treated for primary pulmonary carcinoid tumor at a single institution. MATERIALS AND METHODS: All patients with a diagnosis of primary pulmonary carcinoid tumor treated from 1989 to 2009 were reviewed. Data collected included demographics, pathology, tobacco use, clinical presentation, tumor location, tumor spread, treatment, and survival. RESULTS: There were 59 cases of pulmonary carcinoid tumors: 47 typical (80%) and 12 atypical (20%). All but 4 patients underwent surgery, including 54 (92%) lung-sparing resections and 1 pneumonectomy. Five of 55 patients received concurrent adjuvant chemoradiation therapy; 4 patients with atypical and 1 with typical histology. Three additional patients with atypical carcinoid were treated only with adjuvant radiotherapy, palliative radiotherapy, or palliative chemotherapy, respectively. The Kaplan-Meier 5- and 10-year overall survivals were both 80% within the entire population. In the 88% of patients who achieved complete remission, disease-free survival was 98%. A review of a large series from the literature is also presented. CONCLUSIONS: Surgical resection was primary and adequate therapy for most typical carcinoid tumors with high overall survival and disease-free survival. Adjuvant chemotherapy or radiotherapy might be considered for patients with atypical carcinoid tumors who present with adverse pathologic findings.
Authors: Subrato J Deb; Francis C Nichols; Mark S Allen; Claude Deschamps; Stephen D Cassivi; Peter C Pairolero Journal: Ann Thorac Surg Date: 2005-04 Impact factor: 4.330
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: S Bertelsen; A Aasted; C Lund; E Badsberg; I Christoffersen; M Jacobsen; B Skov Jensen; E Ludwigsen; P Paulsen; S M Paulsen Journal: Scand J Thorac Cardiovasc Surg Date: 1985
Authors: Koji Oba; Xavier Paoletti; Steven Alberts; Yung-Jue Bang; Jacqueline Benedetti; Harry Bleiberg; Paul Catalano; Florian Lordick; Stefan Michiels; Satoshi Morita; Yasuo Ohashi; Jean-Pierre Pignon; Philippe Rougier; Mitsuru Sasako; Junichi Sakamoto; Daniel Sargent; Kohei Shitara; Eric Van Cutsem; Marc Buyse; Tomasz Burzykowski Journal: J Natl Cancer Inst Date: 2013-10-09 Impact factor: 13.506
Authors: Ellen M B P Reuling; Chris Dickhoff; Peter W Plaisier; Veerle M H Coupé; Albert H A Mazairac; Rutger J Lely; H Jaap Bonjer; Johannes M A Daniels Journal: Respiration Date: 2018-02-12 Impact factor: 3.580
Authors: Jiandong Zhang; Qiongjie Yu; Yi He; Tingting Hu; Kun Chen; Zhihao Yang; Xingbo Zhang; Dezhi Cheng; Zhifeng He Journal: Technol Cancer Res Treat Date: 2021 Jan-Dec
Authors: Jie Yu; Xin-Hui Jiang; Lian-Fang Du; Min Bai; Zhao-Jun Li; Qiu-Sheng Shi; Qi Jiang; Fan Li Journal: Asian J Androl Date: 2022 Mar-Apr Impact factor: 3.285